Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Head and Neck Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1467631
This article is part of the Research Topic New molecular pathways in thyroid biology: Role of coding and noncoding genes in thyroid pathophysiology, volume II View all 6 articles

Diagnosis and Treatment of Thyroblastoma: A Case Report and Review of Literature

Provisionally accepted
Lijuan Xiong Lijuan Xiong 1,2Xiting Chen Xiting Chen 1,2Hongling Liu Hongling Liu 2*Haoqiang Wang Haoqiang Wang 2Donghai Cheng Donghai Cheng 2*Wei Wang Wei Wang 3Wenyuan He Wenyuan He 3*Bo Xie Bo Xie 4*Juan Zhou Juan Zhou 2*
  • 1 Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province, China
  • 2 Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, China
  • 3 Department of Pathology, General Hospital of Southern Theater Command, Guangzhou, China
  • 4 510010, Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, China

The final, formatted version of the article will be published soon.

    The diagnosis of thyroblastoma initially identified as a thyroid malignant teratoma was subsequently classified as a distinct entity by the World Health Organization (WHO) in 2022. This classification was based on the observation that the tumor presents with independent primitive multilineage elements and is frequently associated with DICER1 hotspot mutations.The objective of this study was to explore and investigate the clinicopathologic characteristics, molecular features and treatment strategies of patients with thyroblastoma, followed by a review of the previous relevant literature. Methods: The clinical manifestations, pathological characteristics, molecular features and treatment strategies of the initial case of thyroblastoma pathologically confirmed in China were analyzed. Results: The tumor was revealed to have high invasive potential, rapid disease progression, and primitive multilineage elements of pathology, including immature thyroid epithelium, spindled mesenchymal proliferations, and neuroepithelial blastema. Next-generation sequencing (NGS) confirmed the presence of germline DICER1 heterozygous pathogenic mutation at p.G1784* in patient, accompanied by the somatic hotspot mutation at p.E1813D of the RNase Ⅲb domain. Despite local thyroid tumor resection, the disease continued to progress rapidly. However, chemotherapy with BEP led to a reduction in the tumor. The patient's progression-free survival (PFS) reached 15 months following the administration of BEP chemotherapy in conjunction with local radiotherapy. The patient ultimately died of cardiac arrest resulting from the progression of the cancer thrombus to the right atrium and right ventricle.Although thyroblastoma has been treated as a separate entity with its distinctive morphologic and molecular characteristics, its clinicopathological features, diagnosis and treatment methods and prognosis remain poorly understood, which requires more accumulated clinical case data to provide basis for the correct diagnosis and treatment in the future.

    Keywords: DIcer1, Thyroblastoma, Thyroid Neoplasms, thyroid, Diagnosis and treatment

    Received: 20 Jul 2024; Accepted: 24 Jan 2025.

    Copyright: © 2025 Xiong, Chen, Liu, Wang, Cheng, Wang, He, Xie and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hongling Liu, Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, China
    Donghai Cheng, Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, China
    Wenyuan He, Department of Pathology, General Hospital of Southern Theater Command, Guangzhou, China
    Bo Xie, 510010, Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, China
    Juan Zhou, Department of Oncology, General Hospital of Southern Theater Command, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.